Form 4: Vicarious Surgical CTO Granted Stock Options

Vicarious Surgical Inc.'s Chief Technology Officer, Sammy Khalifa, was granted 25,025 stock options with an exercise price of $7.61.

Summary

• Sammy Khalifa, Chief Technology Officer, Director, and 10% Owner of Vicarious Surgical Inc. (RBOT), was granted 25,025 stock options.
• The stock options have an exercise price of $7.61 per share.
• The grant date for these options was June 27, 2025.
• The options are set to expire on June 26, 2035.
• The underlying shares will vest in 48 equal monthly installments, commencing one month after the grant date, contingent upon the Reporting Person's continued service.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign of commitment and incentive alignment, though it implies future potential dilution. It's a standard compensation event.

Positives

• The grant of stock options aligns the interests of the Chief Technology Officer with shareholders, incentivizing long-term performance and value creation.
• The four-year vesting schedule encourages the retention of a key management personnel, ensuring continuity in leadership and strategic execution.

Negatives

• Potential for future dilution of existing shares if all granted options are exercised.

Risks

• The ultimate value of the options is dependent on the future market price of Vicarious Surgical Inc. Class A Common Stock, which is subject to market volatility.
• Vesting of the options is contingent on the Reporting Person's continued service, meaning the options could be forfeited if employment ceases before full vesting.

Future Outlook

The vesting schedule of the stock options indicates a long-term commitment to the Chief Technology Officer, aligning with future performance expectations over the next four years.

Industry Context

Granting stock options to key executives like the Chief Technology Officer is a standard practice in the technology and medical device industries to attract, retain, and incentivize talent, particularly in growth-oriented companies like Vicarious Surgical Inc.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a common compensation structure for executives in the medical robotics and surgical technology sector, similar to practices observed at companies like Intuitive Surgical (ISRG) or Stryker (SYK) for their R&D and technology leadership.
• An exercise price of $7.61, which is likely the market price on the grant date, is typical for at-the-money option grants to align executive incentives directly with future stock price appreciation.

Related Party Transactions

• The stock option grant to Sammy Khalifa, who serves as Director, 10% Owner, and Chief Technology Officer, constitutes a related party transaction as it involves a key executive and significant shareholder.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential benefit from increased executive incentive and retention leading to improved company performance.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.

Next Steps

• The underlying shares will vest in 48 equal monthly installments, beginning one month after the grant date of June 27, 2025.
• The options will remain exercisable until their expiration date of June 26, 2035, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a key executive, which is a standard compensation practice aimed at aligning management incentives with shareholder interests. It does not provide new fundamental information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Vicarious Surgical, RBOT, Stock Options, Form 4, Insider Trading, Executive Compensation, Sammy Khalifa, CTO, Equity Grant